Capricor Therapeutics
Market cap $489M 58.1M shares (10-Q, Nov 9, 2026) × $8.41 close Nov 17, 2026
Most recent annual filing: 2026-03-17
- Deramiocel PDUFA dateNov 22, 2026Deramiocel PDUFA date, Nov 22, 2026, thesis-defining
- NS Pharma arbitration corporate updatemid-2027NS Pharma arbitration corporate update, mid-2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
StealthX vaccine
Technology platforms
StealthX
Proprietary exosome-based platform for targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of rare diseases. Development slowed to prioritize Deramiocel pending regulatory clarity.
StealthX · Life Technologies Corporation
CDC-derived exosomes platform technology for therapeutic development; disease focus includes Duchenne muscular dystrophy and other diseases with high unmet medical needs
Capital (as filed)
- Cash
- $44.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $153M Sep 30, 2026
- Operating cash flow
- −$35.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $199M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (14)
- 2026-11-17 UPDATE: Capricor Therapeutics (CAPR) - Tang Capital Walked Out Before the Verdict 🔒 Paid
- 2026-11-11 UPDATE: Capricor Therapeutics (CAPR) - The Last Balance Sheet Before the Binary 🔒 Paid
- 2026-10-06 UPDATE: Capricor Therapeutics (CAPR) - The Before-and-After Picture ★ Distilled Pro
- 2026-08-24 UPDATE: Capricor Therapeutics (CAPR) — The New Date Is November 22 🔒 Paid
- 2026-08-22 UPDATE: Capricor Therapeutics (CAPR) — An Activist Kicks the Door In 🔒 Paid
- 2026-08-15 UPDATE: Capricor Therapeutics (CAPR) — The August 22 Binary Just Got Cancelled 🔒 Paid
- 2026-08-14 UPDATE: Capricor Therapeutics (CAPR) — The Cash Cushion Got Thinner Nine Days Before PDUFA 🔒 Paid
- 2026-08-04 UPDATE: Capricor Therapeutics (CAPR) — RA Capital Just Showed Up 🔒 Paid
- 2026-07-30 UPDATE: Capricor Therapeutics (CAPR) — The Key Secondary Just Lost Its Star 🔒 Paid
- 2026-07-30 UPDATE: Capricor Therapeutics (CAPR) — 9-3 Against, and the Stock Falls Below Cash 🔒 Paid
- 2026-07-28 UPDATE: Capricor Therapeutics (CAPR) — The FDA Showed Its Cards, and the Stock Lost Two-Thirds 🔒 Paid
- 2026-07-14 UPDATE: Capricor Therapeutics (CAPR) — Signing a 138-Month Lease Two Weeks Before AdCom 🔒 Paid
- 2026-06-26 UPDATE: Capricor Therapeutics (CAPR) — A Third Binary Lands on the Calendar 🔒 Paid
- 2026-06-19 Capricor Therapeutics (CAPR) — Scientific Deep Dive for Deramiocel and the StealthX Exosome Platform 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (14 calls)
Every verdict Biotech Distilled has published on Capricor Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-19 Watch Capricor Therapeutics (CAPR) — Scientific Deep Dive for Deramiocel and the StealthX Exosome Platform Real Phase 3 data and best-in-class safety collide with a re-review that already failed once and a commercial structure the company is suing to escape, stacking too many live binaries to commit capital.
- 2026-06-26 Watch UPDATE: Capricor Therapeutics (CAPR) — A Third Binary Lands on the Calendar An FDA-called AdCom adds a third public failure mode without removing either original binary, and none of the upgrade triggers have been met.
- 2026-07-14 Watch UPDATE: Capricor Therapeutics (CAPR) — Signing a 138-Month Lease Two Weeks Before AdCom Management's 138-month lease signals internal confidence in approval, but the trinary of injunction, AdCom, and PDUFA remains intact and none of the upgrade triggers have been met.
- 2026-07-28 Watch UPDATE: Capricor Therapeutics (CAPR) — The FDA Showed Its Cards, and the Stock Lost Two-Thirds FDA briefing documents contest the governing SAP and the stock has collapsed 66%, but the watch-list stance was built for exactly this risk and the binary has repriced rather than resolved.
- 2026-07-30 Watch UPDATE: Capricor Therapeutics (CAPR) — The Key Secondary Just Lost Its Star LVEF revised to p=0.09 by the company's own hand on AdCom morning, leaving only the PUL primary and safety to carry the bull case, with one of three upgrade triggers now met via Lancet publication.
- 2026-07-30 Watch UPDATE: Capricor Therapeutics (CAPR) — 9-3 Against, and the Stock Falls Below Cash A 9-3 panel vote against effectiveness in DMD cardiomyopathy makes a CRL the modal outcome, but the stock now trades below cash creating asymmetry that speculative capital might find interesting.
- 2026-08-04 Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — RA Capital Just Showed Up RA Capital crossing 5% during the briefing-book collapse retires the 'no conviction money' bear-case pillar, and with market cap below cash and a ~$150–200M PRV as optionality, the risk/reward has genuinely shifted.
- 2026-08-14 Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — The Cash Cushion Got Thinner Nine Days Before PDUFA Cash fell to $237.9M and burn accelerated, but the upgrade rationale remains intact at a slightly shallower margin with the NS injunction withdrawn to arbitration and commercial readiness throttled.
- 2026-08-15 Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — The August 22 Binary Just Got Cancelled FDA agreed to review a BLA amendment with 24-month OLE data for a refined upper-limb indication, converting a near-certain CRL binary into a multi-month process, while Tang Capital at 7.1% further retires the 'no conviction money' bear case.
- 2026-08-22 Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — An Activist Kicks the Door In Kaos Capital's activist campaign validates the burn-rate concern and creates pressure to fix it, while the holder base has fully inverted from retail-driven to organized specialist ownership, though the BLA amendment remains the whole ballgame.
- 2026-08-24 Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) — The New Date Is November 22 FDA formally accepted the major amendment and set November 22 as the new PDUFA, confirming the refined upper-limb indication path, though the lease kill switch now has only 39 days of buffer after the decision date.
- 2026-10-06 Speculative buy speculative UPDATE: Capricor Therapeutics (CAPR) - The Before-and-After Picture 24-month OLE crossover data shows a 76% reduction in arm-function decline in former placebo patients and no fading in early-start patients, passing the durability test the amendment needed, though the evidence remains uncontrolled and the asset premium has widened.
- 2026-11-11 Hold UPDATE: Capricor Therapeutics (CAPR) - The Last Balance Sheet Before the Binary At $8.87 the market cap embeds a ~$317M asset premium well above the PRV value, flipping the asymmetry from favorable to roughly symmetric, making trimming into the binary reasonable for holders while new money has little reason to step in.
- 2026-11-17 Hold UPDATE: Capricor Therapeutics (CAPR) - Tang Capital Walked Out Before the Verdict Tang Capital's full exit by September 30 removes the larger specialist anchor and weakens the downside cushion, reinforcing the case for trimming before November 22 while the evidence base and roughly symmetric risk/reward are unchanged.
- Long call · opened Aug 4, 2026 at $4.17 · +101.7% vs XBI -4.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Following the FDA’s extension of the PDUFA target action date to November 22, 2026, the Company updated its estimated contractual and rent commencement dates to November 22, 2026 and November 22, 2027, respectively, and remeasured the lease, resulting in an increase to the lease liability and the ROU asset of approximately $ 73,000 .”
matched to Deramiocel · regulatory decision
-
-
-
“In measuring the right-of-use asset and lease liability, the Company estimated the contractual commencement date of the ARE Lease to be August 22, 2026, the Prescription Drug User Fee Act (“PDUFA”) target action date for Deramiocel, representing management’s best estimate of the date on which the FDA approval contingency will be resolved, and the resulting rent commencement date to be August 22, 2027.”
matched to Deramiocel · regulatory decision
-
-
-
“We remain focused on working with the FDA toward approval ahead of the August 22, 2026, PDUFA target action date.”
matched to Deramiocel · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (29)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseCapricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateWith the November 22 PDUFA twelve days away, Capricor's Q3 10-Q shows cash down to ~$198.5M, a 10% workforce cut, the NS arbitration pushed to mid-2027, and an AHA award for the cardiac data — the last status check before the binary.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseCapricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
- Nov 3, 2026ReleaseCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
- Oct 5, 2026ReleaseCapricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress→ BD updateThe 24-month HOPE-3 OLE data just landed publicly at WMS — patients who spent a year on placebo then switched to Deramiocel slowed their upper limb decline by 76%, and both arms outperformed natural-history predictions at month 24, giving the FDA's November 22 review its first durability signal.BD extracted 1 program update from this document → CAPR pipeline
- Sep 17, 2026ReleaseCapricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society CongressBD extracted 1 program update from this document → CAPR pipeline
- Aug 24, 2026ReleaseCapricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA→ BD updateSummary on the 8-KBD extracted 1 program update from this document → CAPR pipeline
- Aug 24, 20268-KCurrent report: other events · EX-99.1→ BD updateThe FDA has formally accepted Capricor's BLA amendment as a major amendment and set November 22 as the new PDUFA date — the August 22 binary is officially closed, the skeletal-only refined indication strategy is now the company's official regulatory path, and the clock running at $40M/quarter just got three months longer.
- Aug 21, 2026ReleaseKaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholdersvia aggregator→ BD update
- Aug 14, 202610-QQuarterly report
- Aug 13, 2026ReleaseCapricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 1 program update from this document → CAPR pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 10, 2026ReleaseCapricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
- Jul 30, 2026ReleaseCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
- Jul 30, 20268-KCurrent report: other events · EX-99
- Jul 29, 2026ReleaseThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
- Jul 29, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → CAPR pipeline
- Jul 27, 2026ReleaseCapricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for DeramiocelBD extracted 1 program update from this document → CAPR pipeline
- Jul 14, 20268-KCurrent report: material agreement, debt / obligation
- Jun 26, 20268-KCurrent report: other events · EX-99.1
- Jun 8, 20268-KCurrent report: shareholder vote
- May 13, 202610-QQuarterly report
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 10, 2026DEF 14AProxy statement
- Mar 17, 202610-KAnnual report
- Mar 12, 20268-KCurrent report: results of operations · EX-99.1
- Mar 10, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD update
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Oct 14, 2026SCHEDULE 13G/A13G amendment
- Sep 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 19, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 3, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 10, 2026ARSAnnual report to shareholders
- Mar 31, 2026PRE 14APRE 14A